Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

November 30, 2015

Study Completion Date

February 29, 2016

Conditions
GlioblastomaGBMGlioma
Interventions
DRUG

Trans Sodium Crocetinate (TSC)

TSC administered intravenously as a bolus injection prior to radiation therapy sessions during 6 weeks of radiotherapy.

Trial Locations (18)

11030

North Shore University Hospital, Manhasset

17033

Penn State University Milton S. Hershey Medical Center, Hershey

20037

The George Washington University Medical Center, Washington D.C.

22908

UVA Health Sciences Center Emily Couric Clinical Cancer Center, Charlottesville

27103

Forsyth Regional Cancer Center, Winston-Salem

29425

Medical University of South Carolina, Charleston

30322

Emory University Winship Cancer Institute, Atlanta

32611

University of Florida McKnight Brain Institute, Gainesville

40536

University of Kentucky Markey Cancer Center, Lexington

53226

Froedtert & Medical College of Wisconsin Cancer Center, Milwaukee

60611

Northwestern University Robert H. Lurie Comprehensive Cancer Center, Chicago

60612

Rush University Medical Center, Chicago

72205

University of Arkansas Winthrop P. Rockefeller Cancer Institute, Little Rock

75246

Baylor University Medical Center, Dallas

77030

University of Texas Health Science Center Memorial Hermann Medical Center, Houston

85013

St. Joseph's Medical Center Barrow Neurology Clinics, Phoenix

90033

USC/Norris Comprehensive Cancer Center, Los Angeles

90048

Cedars-Sinai Medical Center, Los Angeles

Sponsors
All Listed Sponsors
lead

Diffusion Pharmaceuticals Inc

INDUSTRY